Impax Laboratories (IPXL) Tops Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Impax's (IPXL) Guidance Disappoints But Excludes Hidden Opportunity - RBC
February 23, 2016 7:00 AM ESTRBC Capital analyst, Randall Stanicky, cut estimates on Impax Laboratories (NASDAQ: IPXL) after guidance that was much weaker than expectations but notes that call options in the form of Welchol and Renvela are not embedded in expectations. No change to the Sector Perform rating but the PT drops to $40 from $48.
Revenue guidance of 15%+ was above consensus and reasonable. It reflects 12-14 generic launches including 6-8 ANDA approvals (of the 25 ANDA pipeline)... More
